Patent · US Active

Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF

US10905746B2 · kind B2 · utility

1Cited by

10References

36Claims

0Family size

Assignee

Baxalta Incorporated · CH

Inventors

Miranda Chapman · Wellesley, US
Bruce Ewenstein · Brookline, US
Bettina Ploder · Wien, AT

Key dates

Filing date	Feb 26, 2020
Grant date	Feb 2, 2021
Priority date	—
Expiry date	Feb 26, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P7/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.